|
Match
|
Document |
Document Title |
|
|
US20110171325 |
Systems and Methods for Treating Pain Using Brain Stimulation
The invention comprises systems and methods for treating nociceptive pain including at least one force-regulatable device in mechanical, electrical, or chemical communication with at least one...
|
|
|
US20100310599 |
Orally Bioavailable Lipid-Based Constructs
The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
|
|
|
US20120121540 |
Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).
|
|
|
US20100323978 |
Non-aqueous oil delivery system for ophthalmic drugs
The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil...
|
|
|
US20110105497 |
COMPOUNDS AND METHODS FOR TREATMENT OF CANCER
Compounds for treating, preventing or managing cancer are disclosed. Also provided are methods for using the compounds in treatment of various cancers. Also provided are methods of treatment using...
|
|
|
US20120053177 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
|
|
|
US20110059963 |
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
|
|
|
US20110003808 |
OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT
This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of...
|
|
|
US20110269768 |
UROTENSIN II RECEPTOR ANTAGONISTS
This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L2 are as defined herein and their use as urotensin II receptor antagonists.
|
|
|
US20110251211 |
METHODS OF USING SUBSTITUTED ISOXAZOLO PYRIDINONES AS DISSOCIATED GLUCOCORTICOIDS
A method for treating a subject having an inflammatory or auto-immune disease with a substituted isoxazolo pyridinone. Also, a method for administering a substituted isoxazolo pyridinone to a cell...
|
|
|
US20070027140 |
N-heteroaryl indole carboxamides and analogues thereof, for use as glcokinase activators in the treatment of diabetes
This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase...
|
|
|
US20060217394 |
Treatment of anhedonia
A therapeutic method for the enhancement of mood in patients afflicted with iatrogenic anhedonia secondary to chronic increases in the availability and/or efficiency of serotonin, with or without...
|
|
|
US20110065628 |
Medication Combinations for the Treatment of Alcoholism and Drug Addiction
The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders...
|
|
|
US20120108590 |
MELT-EXTRUDED SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that...
|
|
|
US20100305103 |
GENES DIFFERENTIALLY EXPRESSED IN BIPOLAR DISORDER AND/OR SCHIZOPHRENIA
This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or...
|
|
|
US20110082130 |
PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES
Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to...
|
|
|
US20110224172 |
Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods
Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these...
|
|
|
US20110112077 |
Quinolizidinone m1 Receptor Positive Allosteric Modulators
The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is...
|
|
|
US20110206782 |
PIPERIDINE MODULATORS OF DOPAMINE RECEPTOR
The present invention relates to new piperidine modulators of dopamine receptors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
|
US20110117215 |
Microsatellite Markers of Schizophrenia
The invention includes method of determining if a subject is at risk for developing schizophrenia (SZ), schizotypal personality disorder (SPD), or schizoaffective disorder (SD).
|
|
|
US20110053953 |
AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613
Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compounds and pharmaceutical...
|
|
|
US20110059982 |
AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
Azaindole derivative compounds are described. The compounds have an optionally substituted azaindole core linked to a carbocyclic ring having at least one nitrogen atom and further bound to an...
|
|
|
US20090156606 |
OPTICAL CORRECTION
The present disclosure describes compositions which improve visual acuity and to methods for their use.
|
|
|
US20110166060 |
TYMPANIC MEMBRANE PERMEATING EAR DROPS AND USES THEREOF
The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration...
|
|
|
US20110311516 |
Chemically Programmed Vaccination
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with...
|
|
|
US20110124628 |
APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic...
|
|
|
US20100305122 |
APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic...
|
|
|
US20110045076 |
LINEAR ORDER RELEASE POLYMER
Intravaginal drug delivery devices, including intravaginal rings, are provided herein. The devices comprise a polyether urethane composition and a pharmaceutically effective amount of at least one...
|
|
|
US20110263592 |
IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
Imidazo[1,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions ...
|
|
|
US20110190260 |
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
[1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the...
|
|
|
US20110021516 |
MONOCYCLIC CGRP RECEPTOR ANTAGONISTS
The present invention is directed to compounds of the formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, A8, G1, G2, G3, G4, J, Q, Ea, Eb, Ec, R6, R7, RPG and Y are as described herein)...
|
|
|
US20110288074 |
NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF
The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment...
|
|
|
US20120129853 |
METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS
This invention pertains to methods of treating systemic lupus erythematosus, lupus nephritis or Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic...
|
|
|
US20120046246 |
METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF
This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for...
|
|
|
US20100324065 |
Compounds and methods for development of Ret Modulators
Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use...
|
|
|
US20110098291 |
ANTAGONIST OF SMOOTHENED
Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the...
|
|
|
US20050165000 |
Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
Pharmaceutical compositions comprise a therapeutically effective amount of an 8-hydroxy-1,6-naphthyridine-7-carboxamide of Formula (I), or a pharmaceutically acceptable salt thereof: and a nonionic...
|
|
|
US20110086846 |
Azaindazole Compounds As CCR1 Receptor Antagonists
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such...
|
|
|
US20120088752 |
HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF
Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications.
|
|
|
US20100029678 |
DIURETICS
A compound having the structure wherein X is selected from the group consisting of:a bond, —NHCH2(CH2)nCH2OC(O)—, —CH2NHC(O)CH2NHC(O)—, —CH2OC(O)—, —OCH(CH3)OC(O)—, —OCH2OC(O)—,—O—...
|
|
|
US20100190731 |
METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS
The invention relates to methods of treating patients who have suffered an acute myocardial infarction (AMI) with a therapeutic that has anti-fibrotic effects, for example, pirfenidone and analogs...
|
|
|
US20110224191 |
Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines
Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including...
|
|
|
US20120053175 |
MLK INHIBITORS AND METHODS OF USE
Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods...
|
|
|
US20120094944 |
NOVEL IMIDAZOPYRIDINE COMPOUND
For the prevention and/or treatment of chymase-mediated diseases such as skin diseases, circulatory diseases, digestive system diseases, respiratory diseases, liver diseases, ocular diseases or the...
|
|
|
US20090203677 |
Dual Pharmacophores - PDE4-Muscarinic Antagonistics
The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive...
|
|
|
US20120015926 |
COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which...
|
|
|
US20110301127 |
METHODS OF REDUCING MICROBIAL RESISTANCE TO DRUGS
The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly...
|
|
|
US20110015156 |
HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.
|
|
|
US20110021535 |
Trazodone Composition for Once a Day Administration
The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that,...
|
|
|
US20110015205 |
Trazodone Composition for Once a Day Administration
The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that,...
|